Crystalline Polymorph

Crystalline polymorphs represent distinct crystal lattice arrangements of identical molecular compositions exhibiting differing physical properties including melting points, solubility, bioavailability, and stability characteristics. Polymorphic forms arise from different molecular packing arrangements during crystallisation producing metastable, stable, or intermediate thermodynamic states. Regulatory frameworks require identification and characterisation of all crystalline forms that may be present during manufacturing or storage. Stability studies assess polymorph conversion risk during product shelf life, with some metastable forms converting to thermodynamically favourable structures compromising therapeutic efficacy.

Critical quality attributes must specify target polymorphic forms as unintended conversion can substantially alter bioavailability. Manufacturing processes require careful control of crystallisation conditions including solvent selection, temperature profiles, and nucleation management to achieve consistent polymorphic composition. Analytical methods including X-ray powder diffraction, infrared spectroscopy, and Raman spectroscopy enable polymorphic characterisation and quantitation. Regulatory submissions include detailed polymorph characterisation, justification for selected form selection, and conversion risk mitigation strategies. High-profile regulatory actions resulted from uncontrolled polymorph conversion causing bioavailability loss, emphasising polymorph management critical importance.